Citations (87)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Tejashree Waghule, Ranendra Narayan Saha & Gautam Singhvi. (2023) Exploring microfluidics and membrane extrusion for the formulation of temozolomide-loaded liposomes: investigating the effect of formulation and process variables. Journal of Liposome Research 33:2, pages 170-182.
Read now
Read now
Renata S. Auriemma, Ludovica F. S. Grasso, Rosario Pivonello & Annamaria Colao. (2016) The safety of treatments for prolactinomas. Expert Opinion on Drug Safety 15:4, pages 503-512.
Read now
Read now
Antonella Sistigu, Gwenola Manic, Florine Obrist & Ilio Vitale. (2016) Trial watch – inhibiting PARP enzymes for anticancer therapy. Molecular & Cellular Oncology 3:2.
Read now
Read now
Gwenola Manic, Florine Obrist, Antonella Sistigu & Ilio Vitale. (2015) Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy. Molecular & Cellular Oncology 2:4.
Read now
Read now
Gwenola Manic, Florine Obrist, Guido Kroemer, Ilio Vitale & Lorenzo Galluzzi. (2014) Chloroquine and hydroxychloroquine for cancer therapy. Molecular & Cellular Oncology 1:1.
Read now
Read now
Melissa J Siegel, Jonathan L Finlay & Stergios Zacharoulis. (2006) State of the art chemotherapeutic management of pediatric brain tumors. Expert Review of Neurotherapeutics 6:5, pages 765-779.
Read now
Read now
Marko B Lens & Tim G Eisen. (2003) Systemic chemotherapy in the treatment of malignant melanoma. Expert Opinion on Pharmacotherapy 4:12, pages 2205-2211.
Read now
Read now
E. Pagani, R. Pepponi, M.P. Fuggetta, S.P. Prete, M. Turriziani, L. Bonmassar, P.M. Lacal, S. Falcinelli, F. Passarelli, F. Guadagni, E. Alvino & S. D'atri. (2003) DNA Repair Enzymes and Cytotoxic Effects of Temozolomide: Comparative Studies Between Tumor Cells and Normal Cells of the Immune System. Journal of Chemotherapy 15:2, pages 173-183.
Read now
Read now
Articles from other publishers (79)
Bernd Kaina. (2023) Temozolomide, Procarbazine and Nitrosoureas in the Therapy of Malignant Gliomas: Update of Mechanisms, Drug Resistance and Therapeutic Implications. Journal of Clinical Medicine 12:23, pages 7442.
Crossref
Crossref
William H. Pentz, Vincenzo J. Pizzuti, Matthew E. Halbert, Tritan J. Plute, Paul R. Lockman & Samuel A. Sprowls. (2023) An Overview of Nanotherapeutic Drug Delivery Options for the Management of Glioblastoma. Journal of Nanotheranostics 4:3, pages 323-345.
Crossref
Crossref
Ondrej Honc & Jiri Novotny. (2023) Methadone Potentiates the Cytotoxicity of Temozolomide by Impairing Calcium Homeostasis and Dysregulation of PARP in Glioblastoma Cells. Cancers 15:14, pages 3567.
Crossref
Crossref
Dzohara Murillo, Carmen Huergo, Borja Gallego, René Rodríguez & Juan Tornín. (2023) Exploring the Use of Cold Atmospheric Plasma to Overcome Drug Resistance in Cancer. Biomedicines 11:1, pages 208.
Crossref
Crossref
Meixiong Cheng, Qi Wang, Longyi Chen, Dongdong Zhao, Jian Tang, Jianguo Xu & Zongze He. (2022) LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways. Human Pathology 123, pages 59-73.
Crossref
Crossref
Yi Yang & Wenbo Zhan. (2022) Role of Tissue Hydraulic Permeability in Convection-Enhanced Delivery of Nanoparticle-Encapsulated Chemotherapy Drugs to Brain Tumour. Pharmaceutical Research 39:5, pages 877-892.
Crossref
Crossref
Lea Beltzig, Christian Schwarzenbach, Petra Leukel, Katrin B. M. Frauenknecht, Clemens Sommer, Alessandro Tancredi, Monika E. Hegi, Markus Christmann & Bernd Kaina. (2022) Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells. Cancers 14:9, pages 2233.
Crossref
Crossref
Tejashree Waghule, K. Laxmi Swetha, Aniruddha Roy, Ranendra Narayan Saha & Gautam Singhvi. (2022) Quality by design assisted optimization of temozolomide loaded PEGylated lyotropic liquid crystals: Investigating various formulation and process variables along with in-vitro characterization. Journal of Molecular Liquids 352, pages 118724.
Crossref
Crossref
Stefaan W. Van Gool, Jennifer Makalowski, Michael Bitar, Peter Van de Vliet, Volker Schirrmacher & Wilfried Stuecker. (2022) Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients. Genes & Immunity 23:8, pages 255-259.
Crossref
Crossref
Federica Fabro, Martine L. M. Lamfers & Sieger Leenstra. (2022) Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors. Cancers 14:3, pages 600.
Crossref
Crossref
Lea Beltzig, Björn Stratenwerth & Bernd Kaina. (2021) Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma Cells. Cancers 13:24, pages 6287.
Crossref
Crossref
Björn Stratenwerth, Susanne M. Geisen, Yang He, Lea Beltzig, Shana J. Sturla & Bernd Kaina. (2021) Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold Doses. Molecular Cancer Therapeutics 20:10, pages 1789-1799.
Crossref
Crossref
Birgitta I. Hiddinga, Jo Raskin, Annelies Janssens, Patrick Pauwels & Jan P. Van Meerbeeck. (2021) Recent developments in the treatment of small cell lung cancer. European Respiratory Review 30:161, pages 210079.
Crossref
Crossref
Satya Das, Taymeyah Al-Toubah & Jonathan Strosberg. (2021) Chemotherapy in Neuroendocrine Tumors. Cancers 13:19, pages 4872.
Crossref
Crossref
Yang‐Bao Miao, Kuan‐Hung Chen, Chiung‐Tong Chen, Fwu‐Long Mi, Yu‐Jung Lin, Yen Chang, Chi‐Shiun Chiang, Jui‐To Wang, Kun‐Ju Lin & Hsing‐Wen Sung. (2021) A Noninvasive Gut‐to‐Brain Oral Drug Delivery System for Treating Brain Tumors. Advanced Materials 33:34, pages 2100701.
Crossref
Crossref
Jason P. Lambden, Max F. Kelsten, Brian C. Schulte, Susan Abbinanti, John P. Hayes, Victoria Villaflor & Mark Agulnik. (2021) Metastatic Myxofibrosarcoma with Durable Response to Temozolomide Followed by Atezolizumab: A Case Report. The Oncologist 26:7, pages 549-553.
Crossref
Crossref
Javier A. Jacobo, Sonia Mejia-Perez & Sergio Moreno-Jimenez. (2021) The Role of Neoadjuvant Therapy to Improve the Extent of Resection in “Unresectable” Gliomas. World Neurosurgery 146, pages 53-58.
Crossref
Crossref
Khawla Yahiaoui, Lynda Seridi & Karima Mansouri. (2020) Temozolomide binding to Cucurbit[7]uril: QTAIM, NCI-RDG and NBO analyses. Journal of Inclusion Phenomena and Macrocyclic Chemistry 99:1-2, pages 61-77.
Crossref
Crossref
Farshid Zandsalimi, Shahin Aghamiri, Soheil Roshanzamiri, Shiva Shahmohamadnejad & Hossein Ghanbarian. (2020) The emerging role of cold atmospheric plasma in glioblastoma therapy. Plasma Processes and Polymers 17:10, pages 1900189.
Crossref
Crossref
Susan G. R. McDuff, Jorg Dietrich, Katelyn M. Atkins, Kevin S. Oh, Jay S. Loeffler & Helen A. Shih. (2019) Radiation and chemotherapy for high‐risk lower grade gliomas: Choosing between temozolomide and PCV. Cancer Medicine 9:1, pages 3-11.
Crossref
Crossref
Yang He & Bernd Kaina. (2019) Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?. International Journal of Molecular Sciences 20:7, pages 1562.
Crossref
Crossref
Wenbo Zhan. (2019) Delivery of liposome encapsulated temozolomide to brain tumour: Understanding the drug transport for optimisation. International Journal of Pharmaceutics 557, pages 280-292.
Crossref
Crossref
Yichun He, Hao Meng, Huadan Xu, Linghua Fan, Zijian Zhou, Bo Xu, Liankun Sun & Yufei Gao. (2018) Regulation of Integrated Stress Response Sensitizes U87MG Glioblastoma Cells to Temozolomide Through the Mitochondrial Apoptosis Pathway. The Anatomical Record 301:8, pages 1390-1397.
Crossref
Crossref
Gerald Raverot, Pia Burman, Ann McCormack, Anthony Heaney, Stephan Petersenn, Vera Popovic, Jacqueline Trouillas, Olaf M Dekkers & _ _. (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. European Journal of Endocrinology 178:1, pages G1-G24.
Crossref
Crossref
Herbert B. Newton. 2018. Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy. Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy
399
409
.
Birgitta I. Hiddinga, Patrick Pauwels, Annelies Janssens & Jan P. van Meerbeeck. (2017) O 6 -Methylguanine-DNA methyltransferase (MGMT): A drugable target in lung cancer?. Lung Cancer 107, pages 91-99.
Crossref
Crossref
PSS Rao & Christopher RT Stang. 2017. Advances in Personalized Nanotherapeutics. Advances in Personalized Nanotherapeutics
79
95
.
Monica Marzagalli, Marina Montagnani Marelli, Lavinia Casati, Fabrizio Fontana, Roberta Manuela Moretti & Patrizia Limonta. (2016) Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility. Frontiers in Endocrinology 7.
Crossref
Crossref
Liang BaoLei LvJinping FengYuyu ChenXinhua WangShuguang HanHongqing Zhao. (2016) miR-487b-5p Regulates Temozolomide Resistance of Lung Cancer Cells Through LAMP2-Medicated Autophagy. DNA and Cell Biology 35:8, pages 385-392.
Crossref
Crossref
Qian Zhao, Qin Qin, Jinglong Sun, Dan Han, Zhongtang Wang, Junjie Teng & Baosheng Li. (2016) Brain Radiotherapy plus Concurrent Temozolomide versus Radiotherapy Alone for Patients with Brain Metastases: A Meta-Analysis. PLOS ONE 11:3, pages e0150419.
Crossref
Crossref
Yusuke Nitta, Saki Shimizu, Yukiko Shishido‐Hara, Kaori Suzuki, Yoshiaki Shiokawa & Motoo Nagane. (2016)
Nimotuzumab enhances temozolomide‐induced growth suppression of glioma cells expressing mutant
EGFR
in vivo
. Cancer Medicine 5:3, pages 486-499.
Crossref
Crossref
Bhavana Singh & April Salama. (2016) Updates in Therapy for Advanced Melanoma. Cancers 8:1, pages 17.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
495
547
.
Olga Martinho, Natália Vilaça, Paulo J. G. Castro, Ricardo Amorim, António M. Fonseca, Fátima Baltazar, Rui M. Reis & Isabel C. Neves. (2015) In vitro and in vivo studies of temozolomide loading in zeolite structures as drug delivery systems for glioblastoma. RSC Advances 5:36, pages 28219-28227.
Crossref
Crossref
Javier Aller Pardo, Mariana Campderá Michelena, Nuria Palacios García & Javier Estrada García. 2015. Actualización en neuroendocrinología. Actualización en neuroendocrinología
171
198
.
Ashley K. Clift, Nicholas Coupe & Mark R. Middleton. 2015. PARP Inhibitors for Cancer Therapy. PARP Inhibitors for Cancer Therapy
511
531
.
XIAOLING SHE, ZHIBIN YU, YULONG CUI, QIANQIAN LEI, ZEYOU WANG, GANG XU, JUANJUAN XIANG, MINGHUA WU & GUIYUAN LI. (2014) miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. Oncology Reports 32:3, pages 957-964.
Crossref
Crossref
Jennifer Wang, Caimiao Wei, Rahat Noor, Anahit Burke, Susan McIntyre & Agop Y. Bedikian. (2014) Surveillance for brain metastases in patients receiving systemic therapy for advanced melanoma. Melanoma Research 24:1, pages 54-60.
Crossref
Crossref
R. Dubrow, A. S. Darefsky, D. I. Jacobs, L. S. Park, M. G. Rose, M. S. H. Laurans & J. T. King. (2013) Time trends in glioblastoma multiforme survival: the role of temozolomide. Neuro-Oncology 15:12, pages 1750-1761.
Crossref
Crossref
Ana P. Montaldi & Elza T. Sakamoto-Hojo. (2012) Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide. Clinical and Experimental Medicine 13:4, pages 279-288.
Crossref
Crossref
Felicitas Merz, Frank Gaunitz, Faramarz Dehghani, Christof Renner, Jürgen Meixensberger, Angelika Gutenberg, Alf Giese, Kosta Schopow, Christian Hellwig, Michael Schäfer, Manfred Bauer, Horst Stöcker, Gisela Taucher-Scholz, Marco Durante & Ingo Bechmann. (2013) Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. Neuro-Oncology 15:6, pages 670-681.
Crossref
Crossref
Julia Köritzer, Veronika Boxhammer, Andrea Schäfer, Tetsuji Shimizu, Tobias G. Klämpfl, Yang-Fang Li, Christian Welz, Sabina Schwenk-Zieger, Gregor E. Morfill, Julia L. Zimmermann & Jürgen Schlegel. (2013) Restoration of Sensitivity in Chemo — Resistant Glioma Cells by Cold Atmospheric Plasma. PLoS ONE 8:5, pages e64498.
Crossref
Crossref
Wei Zhu. (2013) Temozolomide for treatment of brain metastases: A review of 21 clinical trials. World Journal of Clinical Oncology 5:1, pages 19.
Crossref
Crossref
Catalin Mihalcioiu. 2013. Experimental and Clinical Metastasis. Experimental and Clinical Metastasis
299
318
.
Amit S. Kalgutkar, Deepak Dalvie, R. Scott Obach & Dennis A. Smith. 2012. Reactive Drug Metabolites. Reactive Drug Metabolites
145
183
.
Amy S. Darefsky, Joseph T. KingJr.Jr. & Robert Dubrow. (2011) Adult glioblastoma multiforme survival in the temozolomide era: A population‐based analysis of Surveillance, Epidemiology, and End Results registries. Cancer 118:8, pages 2163-2172.
Crossref
Crossref
Arman Jahangiri & Manish K. Aghi. (2012) Pseudoprogression and Treatment Effect. Neurosurgery Clinics of North America 23:2, pages 277-287.
Crossref
Crossref
Dongxiao Zhuang, Yingchao Liu, Ying Mao, Liang Gao, Haishi Zhang, Shihai Luan, Fengping Huang & Qingquan Li. (2011) TMZ‐induced PrPc/par‐4 interaction promotes the survival of human glioma cells. International Journal of Cancer 130:2, pages 309-318.
Crossref
Crossref
Andrea Chassot, Sandra Canale, Pascale Varlet, Stephanie Puget, Thomas Roujeau, Laura Negretti, Frederic Dhermain, Xavier Rialland, Marie Anne Raquin, Jacques Grill & Christelle Dufour. (2011) Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Journal of Neuro-Oncology 106:2, pages 399-407.
Crossref
Crossref
Ann I. McCormack, John A. H. Wass & Ashley B. Grossman. (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. European Journal of Clinical Investigation 41:10, pages 1133-1148.
Crossref
Crossref
Michael A. Davies, Ping Liu, Susan McIntyre, Kevin B. Kim, Nicholas Papadopoulos, Wen‐Jen Hwu, Patrick Hwu & Agop Bedikian. (2010) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117:8, pages 1687-1696.
Crossref
Crossref
S. Siena, L. Crinò, M. Danova, S. Del Prete, S. Cascinu, S. Salvagni, I. Schiavetto, M. Vitali & E. Bajetta. (2010) Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Annals of Oncology 21:3, pages 655-661.
Crossref
Crossref
Kari Jacobsen, Johan Tausjø, Bjarne Hager & Stein Gundersen. (2010) Behandling av melanommetastaser på ekstremitetene. Tidsskrift for Den norske legeforening 130:1, pages 21-24.
Crossref
Crossref
Prakash Chinnaiyan, George David Wilson & Paul M. Harari. 2010. Leibel and Phillips Textbook of Radiation Oncology. Leibel and Phillips Textbook of Radiation Oncology
82
94
.
Holly J. Meany, Katherine E. Warren, Elizabeth Fox, Diane E. Cole, Alberta A. Aikin & Frank M. Balis. (2009) Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. Cancer Chemotherapy and Pharmacology 65:1, pages 137-142.
Crossref
Crossref
Marianne Schrader de Oliveira, Giovana Cechim, Elisandra Braganhol, Daniel Garcia Santos, Luise Meurer, Cláudio Galvão de CastroJrJr, Algemir Lunardi Brunetto, Gilberto Schwarstmann, Ana Maria Oliveira Battastini, Guido Lenz & Rafael Roesler. (2009) Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. Journal of Neuro-Oncology 93:2, pages 191-201.
Crossref
Crossref
Rüdiger Pipkorn, Waldemar Waldeck, Bernd Didinger, Mario Koch, Gabriele Mueller, Manfred Wiessler & Klaus Braun. (2009) Inverse-electron-demand Diels-Alder reaction as a highly efficient chemoselective ligation procedure: Synthesis and function of a BioShuttle for temozolomide transport into prostate cancer cells. Journal of Peptide Science 15:3, pages 235-241.
Crossref
Crossref
Lula Rosso, Cathryn S. Brock, James M. Gallo, Azeem Saleem, Patricia M. Price, Federico E. Turkheimer & Eric O. Aboagye. (2009) A New Model for Prediction of Drug Distribution in Tumor and Normal Tissues: Pharmacokinetics of Temozolomide in Glioma Patients. Cancer Research 69:1, pages 120-127.
Crossref
Crossref
Ruth Plummer, Christopher Jones, Mark Middleton, Richard Wilson, Jeffrey Evans, Anna Olsen, Nicola Curtin, Alan Boddy, Peter McHugh, David Newell, Adrian Harris, Patrick Johnson, Heidi Steinfeldt, Raz Dewji, Diane Wang, Lesley Robson & Hilary Calvert. (2008) Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors. Clinical Cancer Research 14:23, pages 7917-7923.
Crossref
Crossref
Steve R. Martinez & Shawn E. Young. (2008) A rational surgical approach to the treatment of distant melanoma metastases. Cancer Treatment Reviews 34:7, pages 614-620.
Crossref
Crossref
Jann N. Sarkaria, Gaspar J. Kitange, C. David James, Ruth Plummer, Hilary Calvert, Michael Weller & Wolfgang Wick. (2008) Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma. Clinical Cancer Research 14:10, pages 2900-2908.
Crossref
Crossref
Dieta Brandsma, Lukas Stalpers, Walter Taal, Peter Sminia & Martin J van den Bent. (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. The Lancet Oncology 9:5, pages 453-461.
Crossref
Crossref
Pete AndersonDolly AguileraMargaret PearsonShaio Woo. (2008) Outpatient Chemotherapy plus Radiotherapy in Sarcomas: Improving Cancer Control with Radiosensitizing Agents. Cancer Control 15:1, pages 38-46.
Crossref
Crossref
Raffaele Addeo, Michele Caraglia, Vincenzo Faiola, Elena Capasso, Bruno Vincenzi, Liliana Montella, Rosario Guarrasi, Luigi Caserta & Salvatore Del Prete. (2007) Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life. BMC Cancer 7:1.
Crossref
Crossref
D Nashan, ML Müller, S Grabbe, S Wustlich & A Enk. (2007) Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine. Journal of the European Academy of Dermatology and Venereology 21:10, pages 1305-1318.
Crossref
Crossref
R.D. Hubbard & S. Fidanze. 2007. Comprehensive Medicinal Chemistry II. Comprehensive Medicinal Chemistry II
129
148
.
Mark Agulnik & Warren P. Mason. (2006) The Changing Management of Low-Grade Astrocytomas and Oligodendrogliomas. Hematology/Oncology Clinics of North America 20:6, pages 1249-1266.
Crossref
Crossref
A H Yeh, E A Bohula & V M Macaulay. (2006) Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Oncogene 25:50, pages 6574-6581.
Crossref
Crossref
Arnab Chakravarti, Michael G. Erkkinen, Ulf Nestler, Roger Stupp, Minesh Mehta, Ken Aldape, Mark R. Gilbert, Peter McL. Black & Jay S. Loeffler. (2006) Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms. Clinical Cancer Research 12:15, pages 4738-4746.
Crossref
Crossref
M. Aleem Khan, Stephanie Andrews, Roohi Ismail-Khan, Pamela N. Munster, Steven Brem, Jeff King, Douglas S. ReintgenVernon K. Sondak & Adil I. Daud. (2017) Overall and Progression-Free Survival in Metastatic Melanoma: Analysis of a Single-Institution Database. Cancer Control 13:3, pages 211-217.
Crossref
Crossref
Wen‐Jen Hwu, Katherine S. Panageas, Jennifer H. Menell, Lynne A. Lamb, Suzan Aird, Susan E. Krown, Linda J. Williams, Paul B. Chapman, Philip O. Livingston, Jedd D. Wolchok & Alan N. Houghton. (2006) Phase II study of temozolomide plus pegylated interferon‐α‐2b for metastatic melanoma. Cancer 106:11, pages 2445-2451.
Crossref
Crossref
Herbert B. Newton. 2006. Handbook of Brain Tumor Chemotherapy. Handbook of Brain Tumor Chemotherapy
347
363
.
Michele Caraglia, Raffaele Addeo, Raffaele Costanzo, Liliana Montella, Vincenzo Faiola, Monica Marra, Alberto Abbruzzese, Giovannella Palmieri, Alfredo Budillon, Francesco Grillone, Salvatore Venuta, Pierosandro Tagliaferri & Salvatore Del Prete. (2005) Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemotherapy and Pharmacology 57:1, pages 34-39.
Crossref
Crossref
Jonathan L. Finlay & Stergios Zacharoulis. (2005) The Treatment of High Grade Gliomas and Diffuse Intrinsic Pontine Tumors of Childhood and Adolescence: A Historical – and Futuristic – Perspective. Journal of Neuro-Oncology 75:3, pages 253-266.
Crossref
Crossref
Robert Cavaliere, Maria Beatriz S Lopes & David Schiff. (2005) Low-grade gliomas: an update on pathology and therapy. The Lancet Neurology 4:11, pages 760-770.
Crossref
Crossref
Xuemei Zhang, Irene Lee & Anthony J. Berdis. (2005) A Potential Chemotherapeutic Strategy for the Selective Inhibition of Promutagenic DNA Synthesis by Nonnatural Nucleotides. Biochemistry 44:39, pages 13111-13121.
Crossref
Crossref
E. Ruth Plummer, Mark R. Middleton, Christopher Jones, Anna Olsen, Ian Hickson, Peter McHugh, Geoffrey P. Margison, Gail McGown, Mary Thorncroft, Amanda J. Watson, Alan V. Boddy, A. Hilary Calvert, Adrian L. Harris, David R. Newell & Nicola J. Curtin. (2005)
Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes
O
6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1
. Clinical Cancer Research 11:9, pages 3402-3409.
Crossref
Crossref
Carmen Gil, Anja Schwögler & Stefan Bräse. (2003)
The Synthesis of 3-Substituted 6-Aryl-3
H
-benzo[
a
][1,2,3]triazinones Using Polymer-Bound Triazenes
. Journal of Combinatorial Chemistry 6:1, pages 38-42.
Crossref
Crossref
Josef Jiricny & Giancarlo Marra. (2003) DNA repair defects in colon cancer. Current Opinion in Genetics & Development 13:1, pages 61-69.
Crossref
Crossref